AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24438351 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint counselling and financial support
Number of subjects: 0
Study 24438351 — intervention group
Group type: COMPARATOR
Intervention: No support
Number of subjects: 0
Study 23026182 — intervention group
Group type: EXPERIMENTAL
Intervention: Ragweed sublingual allergy immunotherapy tablet (AIT) at doses of 3, 6, 12, 24, 50, or 100 Amb a 1-U, administered once daily for 28 days
Number of subjects: 53
Study 23026182 — intervention group
Group type: EXPERIMENTAL
Intervention: Ragweed sublingual allergy immunotherapy tablet (AIT)
Number of subjects: 53
Study 23026182 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 19528135 — intervention group
Group type: COMPARATOR
Intervention: Methadone Maintenance Treatment (MMT) alone
Number of subjects: 253
Study 19528135 — intervention group
Group type: EXPERIMENTAL
Intervention: Injectable opioids (diacetylmorphine or hydromorphone) plus adjunctive MMT if deemed appropriate
Number of subjects: 253
Study 17328961 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive group cognitive therapy (IGCT)
Number of subjects: 100
Study 17328961 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual cognitive therapy (ICT)
Number of subjects: 100
Study 17328961 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 100
Study 17328961 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapy (general)
Number of subjects: 100
Study 15229304 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamins (vitamins B, C, and E)
Number of subjects: 1078
Study 15229304 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1078
Study 15229304 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A alone
Number of subjects: 1078
Study 11249054 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin-based chemotherapy
Number of subjects: 585
Study 9722129 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE (0.625 mg/day) plus ipriflavone (600 mg/day)
Number of subjects: 116
Study 9722129 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE (0.625 mg/day)
Number of subjects: 116
Study 9722129 — intervention group
Group type: EXPERIMENTAL
Intervention: ipriflavone (600 mg/day)
Number of subjects: 116
Study 9722129 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 116
Study 8202971 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganglioside GM1 100 mg intramuscularly daily for 28 days
Number of subjects: 287
Study 8202971 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 287
Study 8202971 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganglioside GM1
Number of subjects: 287
Study 8202971 — intervention group
Group type: COMPARATOR
Intervention: Ganglioside GM1 and Placebo
Number of subjects: 287
Study 2562020 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxylapatite (HA) - Interpore 200 implanted into periodontal defects
Number of subjects: 99
Study 2562020 — intervention group
Group type: COMPARATOR
Intervention: Open flap curettage
Number of subjects: 99
Study 2562020 — intervention group
Group type: EXPERIMENTAL
Intervention: Histological evaluation of HA implants
Number of subjects: 99
Study 433813 — intervention group
Group type: EXPERIMENTAL
Intervention: Dealcoholized Zinfandel wine
Number of subjects: 6
Study 433813 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (9.3% w/v aqueous alcohol solution)
Number of subjects: 6
Study 433813 — intervention group
Group type: COMPARATOR
Intervention: Zinfandel wine (9.3% w/v alcohol)
Number of subjects: 6
Study 433813 — intervention group
Group type: COMPARATOR
Intervention: Deionized water
Number of subjects: 6
Study 31144977 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-alanine (BA) supplementation 30 mg•kg‐1
Number of subjects: 11
Study 31144977 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 11
Study 31144977 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-alanine (BA) supplementation
Number of subjects: 11
Study 27647261 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored patient-activation letter communicating BMD test results plus an educational brochure
Number of subjects: 7749
Study 27647261 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 7749
Study 26115073 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal supervised exercise (group exercise classes twice a week for 12 months and once a week for the subsequent 12 months and home exercises)
Number of subjects: 409
Study 26115073 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal supervised exercise
Number of subjects: 409
Study 26115073 — intervention group
Group type: COMPARATOR
Intervention: Control (maintained current physical activity)
Number of subjects: 409
Study 23348607 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib at 5 mg twice daily
Number of subjects: 0
Study 23348607 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib at 10 mg twice daily
Number of subjects: 0
Study 23348607 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21113620 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine and celecoxib
Number of subjects: 110
Study 21113620 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine
Number of subjects: 110
Study 21113620 — intervention group
Group type: COMPARATOR
Intervention: XELOX (capecitabine plus oxaliplatine)
Number of subjects: 110
Study 21113620 — intervention group
Group type: EXPERIMENTAL
Intervention: XELOX + celecoxib
Number of subjects: 110
Study 18403219 — intervention group
Group type: EXPERIMENTAL
Intervention: FREMS
Number of subjects: 31
Study 18403219 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 17653881 — intervention group
Group type: EXPERIMENTAL
Intervention: 20,000 U rhEPO
Number of subjects: 60
Study 17653881 — intervention group
Group type: EXPERIMENTAL
Intervention: 40,000 U rhEPO
Number of subjects: 60
Study 17653881 — intervention group
Group type: COMPARATOR
Intervention: Intravenous iron alone
Number of subjects: 60
Study 14998402 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg day(-1) terbinafine
Number of subjects: 63
Study 14998402 — intervention group
Group type: COMPARATOR
Intervention: 500 mg day(-1) terbinafine
Number of subjects: 63
Study 11320011 — intervention group
Group type: EXPERIMENTAL
Intervention: Verteporfin (6 mg per square meter of body surface area; n = 81)
Number of subjects: 120
Study 11320011 — intervention group
Group type: COMPARATOR
Intervention: Placebo (5% dextrose in water; n = 39)
Number of subjects: 120
Study 9083900 — intervention group
Group type: EXPERIMENTAL
Intervention: Stannous fluoride toothpaste
Number of subjects: 12
Study 9083900 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan/copolymer toothpaste
Number of subjects: 12
Study 9083900 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan/zinc citrate toothpaste
Number of subjects: 12
Study 9083900 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 12
Study 8446045 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperglycemic clamp (HY)
Number of subjects: 17
Study 8446045 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous glucose administration (IV)
Number of subjects: 17
Study 8446045 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous glucose tolerance test (IVGTT)
Number of subjects: 17
Study 8446045 — intervention group
Group type: COMPARATOR
Intervention: Basal proinsulin concentrations
Number of subjects: 17
Study 8446045 — intervention group
Group type: COMPARATOR
Intervention: Basal molar proinsulin:insulin ratio (P:I)
Number of subjects: 17
Study 3513687 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymetazoline 0.025% topical ophthalmic solution
Number of subjects: 39
Study 3513687 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 39
Study 11401762 — intervention group
Group type: EXPERIMENTAL
Intervention: LAN exposure
Number of subjects: 53
Study 11401762 — intervention group
Group type: COMPARATOR
Intervention: EMF exposure
Number of subjects: 53
Study 11401762 — intervention group
Group type: COMPARATOR
Intervention: Women with high or low melatonin secretion
Number of subjects: 53
Study 30497789 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin and low molecular weight dextran (Group A)
Number of subjects: 454
Study 30497789 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (Group B)
Number of subjects: 454
Study 30497789 — intervention group
Group type: COMPARATOR
Intervention: No antithrombotic agent (Group C)
Number of subjects: 454
Study 30012180 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS (20 sessions; 5 consecutive weekdays/wk, 2 mA, 20 minutes) + hypocaloric diet
Number of subjects: 0
Study 30012180 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS + hypocaloric diet
Number of subjects: 0
Study 30012180 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS + hypocaloric diet
Number of subjects: 0
Study 26678652 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapist-guided neck-specific exercise with a behavioural approach (NSEB)
Number of subjects: 140
Study 26678652 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapist-guided neck-specific exercise (NSE)
Number of subjects: 140
Study 26678652 — intervention group
Group type: COMPARATOR
Intervention: General physical activity (PPA)
Number of subjects: 140
Study 24690267 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality Improvement Collaborative (QIC) based on the Breakthrough Series (BTS) model
Number of subjects: 6592
Study 24690267 — intervention group
Group type: COMPARATOR
Intervention: Normal care (Control)
Number of subjects: 6592
Study 22354243 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic transfusion (2 units of erythrocytes transfused 1 to 2 days before surgery)
Number of subjects: 60
Study 22354243 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (transfusions as indicated)
Number of subjects: 60
Study 22354243 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic transfusion
Number of subjects: 60
Study 20385630 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational-book group
Number of subjects: 168
Study 20385630 — intervention group
Group type: COMPARATOR
Intervention: Noneducational-book group
Number of subjects: 168
Study 20385630 — intervention group
Group type: COMPARATOR
Intervention: No-book group
Number of subjects: 168
Study 17481946 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan in patients with acute decompensated HF
Number of subjects: 0
Study 17481946 — intervention group
Group type: EXPERIMENTAL
Intervention: Nesiritide in patients with chronic decompensated HF
Number of subjects: 0
Study 17481946 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure reduction in hypertensive patients
Number of subjects: 0
Study 17481946 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone in mild to moderate chronic HF
Number of subjects: 0
Study 17481946 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG-PET imaging for selecting HF patients for revascularisation
Number of subjects: 0
Study 17481946 — intervention group
Group type: EXPERIMENTAL
Intervention: Crataegus extract added to standard HF therapy
Number of subjects: 0
Study 17481946 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI in patients without HF or major cardiac dysfunction
Number of subjects: 0
Study 17481946 — intervention group
Group type: EXPERIMENTAL
Intervention: HF nurse-intervention in the COACH study
Number of subjects: 0
Study 17481946 — intervention group
Group type: EXPERIMENTAL
Intervention: HF nurse-intervention in the REMADHE study
Number of subjects: 0
Study 17481946 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP for distinguishing cardiac and pulmonary breathlessness
Number of subjects: 0
Study 17481946 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention in post-MI patients (THIS-diet study)
Number of subjects: 0
Study 15592070 — intervention group
Group type: EXPERIMENTAL
Intervention: Webcam trainer
Number of subjects: 42
Study 15592070 — intervention group
Group type: COMPARATOR
Intervention: Video trainer
Number of subjects: 42
Study 15592070 — intervention group
Group type: COMPARATOR
Intervention: Mirror trainer
Number of subjects: 42
Study 15592070 — intervention group
Group type: EXPERIMENTAL
Intervention: All trainers (Webcam, Video, Mirror)
Number of subjects: 42
Study 12150178 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus 19070-2 and Lactobacillus reuteri DSM 12246, 10(10) colony-forming units of each strain, twice daily for 5 days
Number of subjects: 69
Study 12150178 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 12150178 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus 19070-2 and Lactobacillus reuteri DSM 12246
Number of subjects: 69
Study 10453431 — intervention group
Group type: EXPERIMENTAL
Intervention: Coached exercise training
Number of subjects: 49
Study 10453431 — intervention group
Group type: COMPARATOR
Intervention: Monitored exercise training
Number of subjects: 49
Study 7607715 — intervention group
Group type: EXPERIMENTAL
Intervention: Trandolapril 1 mg/d
Number of subjects: 298
Study 7607715 — intervention group
Group type: EXPERIMENTAL
Intervention: Trandolapril 4 mg/d
Number of subjects: 298
Study 7607715 — intervention group
Group type: EXPERIMENTAL
Intervention: Trandolapril (various doses)
Number of subjects: 298
Study 7607715 — intervention group
Group type: EXPERIMENTAL
Intervention: Trandolapril
Number of subjects: 298
Study 7607715 — intervention group
Group type: EXPERIMENTAL
Intervention: Trandolaprilat
Number of subjects: 298
Study 1971861 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (80 mg/day)
Number of subjects: 425
Study 1971861 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 425
Study 654412 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxyfedrine and interval-training
Number of subjects: 23
Study 654412 — intervention group
Group type: COMPARATOR
Intervention: Interval-training alone (placebo group)
Number of subjects: 23
Study 31084516 — intervention group
Group type: EXPERIMENTAL
Intervention: Beetroot juice (BR) supplementation (340 mg/d)
Number of subjects: 11
Study 31084516 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL) supplementation (<2.5 mg/d)
Number of subjects: 11
Study 31084516 — intervention group
Group type: EXPERIMENTAL
Intervention: Beetroot juice (BR) supplementation
Number of subjects: 11
Study 31084516 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL) supplementation
Number of subjects: 11
Study 28424261 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-fat ultra-high temperature (UHT) milk (HTM)
Number of subjects: 37
Study 28424261 — intervention group
Group type: EXPERIMENTAL
Intervention: Unprocessed (raw) milk (UM)
Number of subjects: 37
Study 28424261 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 37
Study 28424261 — intervention group
Group type: COMPARATOR
Intervention: Full-fat UHT milk diluted 1:1 with water (MW)
Number of subjects: 37
Study 28424261 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-fat UHT milk with high-phytate rice (RM)
Number of subjects: 37
Study 28424261 — intervention group
Group type: COMPARATOR
Intervention: Water with high-phytate rice (RW)
Number of subjects: 37
Study 25885544 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard TSST-M condition
Number of subjects: 163
Study 25885544 — intervention group
Group type: COMPARATOR
Intervention: Low-stress TSST-M condition
Number of subjects: 163
Study 24236622 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) with drug-eluting stents
Number of subjects: 1900
Study 24236622 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 1900
Study 21465243 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline for an average of 24 days
Number of subjects: 40
Study 21465243 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 19733706 — intervention group
Group type: EXPERIMENTAL
Intervention: Newly initiated statin therapy (36 patients)
Number of subjects: 74
Study 19733706 — intervention group
Group type: COMPARATOR
Intervention: Long-term statin therapy (38 patients)
Number of subjects: 74
Study 19733706 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 74
Study 19733706 — intervention group
Group type: EXPERIMENTAL
Intervention: Newly initiated statin therapy
Number of subjects: 74
Study 17762662 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan for 48 weeks
Number of subjects: 191
Study 17762662 — intervention group
Group type: COMPARATOR
Intervention: Atenolol for 48 weeks
Number of subjects: 191
Study 17762662 — intervention group
Group type: COMPARATOR
Intervention: Normotensive group
Number of subjects: 191
Study 15243930 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumococcal conjugate vaccine
Number of subjects: 1666
Study 11739431 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 IU/kg BW.wk hGH
Number of subjects: 35
Study 11739431 — intervention group
Group type: COMPARATOR
Intervention: 0.5 IU hGH (for GH deficient group)
Number of subjects: 35
Study 11739431 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 35
Study 11739431 — intervention group
Group type: EXPERIMENTAL
Intervention: hGH treatment
Number of subjects: 35
Study 9406880 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple declarative sentences
Number of subjects: 12
Study 9406880 — intervention group
Group type: EXPERIMENTAL
Intervention: Subordinate clauses
Number of subjects: 12
Study 8501178 — intervention group
Group type: EXPERIMENTAL
Intervention: HMG-GRF (500 micrograms twice daily)
Number of subjects: 13
Study 8501178 — intervention group
Group type: COMPARATOR
Intervention: HMG-placebo
Number of subjects: 13
Study 8501178 — intervention group
Group type: EXPERIMENTAL
Intervention: HMG-GRF
Number of subjects: 13
Study 3306509 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin 40 mg/m2 plus melphalan 0.4 mg/kg every four weeks
Number of subjects: 168
Study 3306509 — intervention group
Group type: COMPARATOR
Intervention: Melphalan 1 mg/kg every four weeks
Number of subjects: 168
Study 29539616 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol (2 sprays of 100 µL/spray in each nostril 3 times/day for 1 month)
Number of subjects: 151
Study 29539616 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (2 sprays of 100 µL/spray in each nostril 3 times/day for 1 month)
Number of subjects: 151
Study 29539616 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 sprays in each nostril 3 times/day for 1 month)
Number of subjects: 151
Study 28317297 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month exercise training
Number of subjects: 248
Study 25729212 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation (8 sessions, 60 minutes each, individual 30 min, group 30 min)
Number of subjects: 43
Study 25729212 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 43
Study 23331722 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention-2 group (diabetes specific 30 minutes counseling session)
Number of subjects: 224
Study 23331722 — intervention group
Group type: COMPARATOR
Intervention: Intervention-1 group (standard cessation advice)
Number of subjects: 224
Study 20931299 — intervention group
Group type: EXPERIMENTAL
Intervention: CT + HV (cisplatin + hydralazine + valproate)
Number of subjects: 36
Study 20931299 — intervention group
Group type: COMPARATOR
Intervention: CT + PLA (cisplatin + placebo)
Number of subjects: 36
Study 18086516 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain self‐management training group (SMG)
Number of subjects: 256
Study 18086516 — intervention group
Group type: COMPARATOR
Intervention: Education-only control condition (BOOK)
Number of subjects: 256
Study 17038905 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate cyclosporine withdrawal and sirolimus introduction (group B, 28 patients)
Number of subjects: 42
Study 17038905 — intervention group
Group type: COMPARATOR
Intervention: 40% cyclosporine reduction (group A, 14 patients)
Number of subjects: 42
Study 12773137 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG-OB (80 mg weekly)
Number of subjects: 24
Study 12773137 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 12773137 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG-OB
Number of subjects: 24
Study 10574137 — intervention group
Group type: EXPERIMENTAL
Intervention: 240 mg glycyrrhizin
Number of subjects: 57
Study 10574137 — intervention group
Group type: EXPERIMENTAL
Intervention: 160 mg glycyrrhizin
Number of subjects: 57
Study 10574137 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg glycyrrhizin
Number of subjects: 57
Study 10574137 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0 mg glycyrrhizin)
Number of subjects: 57
Study 10574137 — intervention group
Group type: EXPERIMENTAL
Intervention: All glycyrrhizin groups
Number of subjects: 57
Study 8764186 — intervention group
Group type: EXPERIMENTAL
Intervention: Overfed and exercised (OF-EX)
Number of subjects: 21
Study 8764186 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercised (EX)
Number of subjects: 21
Study 8764186 — intervention group
Group type: COMPARATOR
Intervention: Overfed (OF)
Number of subjects: 21
Study 8764186 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 21
Study 2063158 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin-G 5 million IU
Number of subjects: 0
Study 2063158 — intervention group
Group type: COMPARATOR
Intervention: Cefuroxime 1.5 g
Number of subjects: 0
Study 6862724 — intervention group
Group type: EXPERIMENTAL
Intervention: Thioridazine (1.0 mg/kg body wt.)
Number of subjects: 0
Study 6862724 — intervention group
Group type: EXPERIMENTAL
Intervention: Thioridazine (1.5 mg/kg body wt.)
Number of subjects: 0
Study 6862724 — intervention group
Group type: EXPERIMENTAL
Intervention: Thioridazine (1.0 and 1.5 mg/kg body wt.)
Number of subjects: 0
Study 6862724 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31855102 — intervention group
Group type: COMPARATOR
Intervention: Endometriosis Health Profile-30 (EHP-30) intervention administered at day 1, month 3 (M3), and month 6 (M6).
Number of subjects: 1686
Study 31855102 — intervention group
Group type: COMPARATOR
Intervention: EHP-30 thresholds of meaningful change.
Number of subjects: 1686